読み込み中
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
前日終値
$12.67
+$0.28 · +2.26%
日中の時刻はETです。市場データは遅延する場合があります。
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
日中レンジ
現在 $12.67
52週レンジ
現在 $12.67
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
75
割安
センチメント
59
まちまち
リスク
51
やや高いリスク
モメンタム
50
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
日中レンジ
現在 $12.67
52週レンジ
現在 $12.67
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 9998.6万 USD | 7990.6万 USD | 6542.1万 USD | 4552万 USD | 4518.3万 USD |
| 売上原価 | 2276.6万 USD | 2082.1万 USD | 1729.9万 USD | 1302.7万 USD | 1174.8万 USD |
| 粗利益 | 7722万 USD | 5908.5万 USD | 4812.2万 USD | 3249.3万 USD | 3343.5万 USD |
| 研究開発 | 2788.8万 USD | 2365.3万 USD | 2077.8万 USD | 2194.6万 USD | 1821.1万 USD |
| 販売・一般管理 | 6567万 USD | 5710.3万 USD | 5451.8万 USD | 5134.1万 USD | 3896.1万 USD |
| 営業費用 | 9355.8万 USD | 8075.6万 USD | 7529.6万 USD | 7328.7万 USD | 5717.2万 USD |
| 受取利息 | 281.6万 USD | 302.4万 USD | 305万 USD | 157.8万 USD | 44.8万 USD |
| 支払利息 | 745.7万 USD | 879.8万 USD | 851.7万 USD | 752.9万 USD | 741万 USD |
| 減価償却費と償却費 | 194.8万 USD | 176.9万 USD | 160.5万 USD | 298.7万 USD | 29.6万 USD |
| 営業利益 | −1633.8万 USD | −2167.1万 USD | −2717.4万 USD | −4079.4万 USD | −2373.7万 USD |
| 純利益 | −2146.5万 USD | −2714.1万 USD | −3295.6万 USD | −4708.2万 USD | −3608万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$20.25
上昇余地（59.83%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1330.92万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM871.98万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF432.28万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO294.88万0.02%139.17億 USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO223.16万0.01%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC102.86万0.08%13.17億 USD0.60%$183+0.11%
State Street SPDR S&P Health Care Equipment ETFXHE58.73万0.34%1.74億 USD0.35%$89.47+1.51%
Vanguard Russell 2000 Growth ETFVTWG42万0.02%17億 USD0.06%$260.49+0.91%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCState Street SPDR S&P Health Care Equipment ETFXHEVanguard Russell 2000 Growth ETFVTWGAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
